Stem Cell

CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present data on the company’s first-in-human clinical study in Parkinson’s disease at Neuroscience 2016.

Session Information

Type: Nanosymposium

Title: Transplants and Other Treatments of Parkinson's Disease

Date: November 14, 2016

Time: 8:00 AM

Location: SDCC 1B, San Diego Convention Center

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranialy transplanted into patients with moderate to severe Parkinson's disease (ClinicalTrials.gov Identifier: NCT02452723). The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC®. PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

The study is underway at The Royal Melbourne Hospital in Australia. The study is being overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd.

2 Replies

oldestnewest
  • I have been following this for over a year now Roy.

    Thank you for the update.

  • I hope this works!

You may also like...